Oncologists Often Favor Immunotherapy Over NGS-Guided Targeted Drugs, Survey Finds – GenomeWeb
|
Oncologists Often Favor Immunotherapy Over NGS-Guided Targeted Drugs, Survey Finds
GenomeWeb A sampling of more than 100 physicians showed that more than two-thirds preferred prescribing patients a type of immunotherapy, called a checkpoint inhibitor, rather than direct them to an experimental targeted drug based on genomic testing. OmniSeq … |
